尿甲醛在阿尔茨海默病诊断中的价值及影响因素  

Diagnostic value of urine formaldehyde in Alzheimer＇ s disease and its influential factors

作　　者：吕继辉[1] 赫荣乔[3] 李文杰[1] 马毅[2] 魏翠柏[4] 秦伟 张研[5] 苏涛[3] 

机构地区：[1]北京老年医院精神心理二科,北京100095 [2]北京老年医院体检中心,北京100095 [3]中国科学院生物物理研究所,北京100101 [4]首都医科大学宣武医院,北京100053 [5]北京大学生命科学学院,北京100871

出　　处：《中华行为医学与脑科学杂志》2017年第7期620-623,共4页Chinese Journal of Behavioral Medicine and Brain Science

摘　　要：目的评估尿甲醛水平检测在阿尔茨海默病（AD）诊断中的价值及AD患者尿甲醛水平的影响因素。方法用队列研究的方法纳入AD患者52名，认知正常者53名。受试者均≥65岁，排除急性感染、心肝肾等重要脏器功能不全。比较两组受试者晨起空腹尿液甲醛水平；多元回归的方法分析AD患者尿液甲醛水平与年龄、性别、发病年龄、认知水平（MMSE评分）、精神症状（NPI评分）、海马萎缩程度（MTA分级）及ApoE84基因的关系。结果AD患者尿甲醛水平高于认知正常者[AD患者：（13．27±4．16）μmol／L；认知正常者：（10．76±4．47）μmoL／L，f=2．99，P=0．15]。MMSE评分（β=-0．35，P：0．03），海马萎缩程度（β=-0．38，P=0．02）是尿甲醛水平的影响因素；性别、年龄、发病年龄、精神症状和是否携带ApoE84基因等对AD患者尿甲醛水平的影响无统计学意义（均P〉0．05）。结论尿液甲醛检测有望成为AD诊断标志物和病情严重程度的评价指标。Objective To explore the value of urine formaldehyde test in the diagnosis of Alzhei- mer＇ s disease （ AD）, and the influential factors of urine formaldehyde level in AD patients. Methods A to- tal of 52 AD patients and 53 cognitively normal controls were recruited in a cohort study. All subjects were no less than 65 years old, and those with acute infection, or dysfunction in heart, liver or kidneys were excluded. The impact of age, gender, onset age, MMSE score, NPI score, MTA score, and ApoE ε4 gene on urine formal- dehyde of AD patients were analyzed by multiple regression analysis. Results Urine formaldehyde level of AD group was statistically higher than that of eognitively normal control group （ （ 13.27± 4.16 ） μmol/L vs （10.76±4.47） μmol/L,t= 2.99 ,P= 0.15 ）. Urine formaldehyde Of AD patients was statistically negatively cor- related with MMSE score （β=-0.35,P=0.03） and MTA score （β=-0.38,P=0.02）. The impact of onset age, neuropsychiatrie disorders and ApoE ε4 gene on urine formaldehyde of AD patients was not statistically significant（ allP〉0.05）. Conclusion Urine formaldehyde level is worthwhile to be explored as a marker in AD diagnosis and severity assessment.

关 键 词：阿尔茨海默病 尿甲醛 APOE e4基因 

分 类 号：R749.16[医药卫生—神经病学与精神病学]